Nuformix plc (LON:NFX – Get Free Report) fell 1.6% on Wednesday . The company traded as low as GBX 0.06 ($0.00) and last traded at GBX 0.06 ($0.00). 13,051,383 shares were traded during mid-day trading, an increase of 124% from the average session volume of 5,828,061 shares. The stock had previously closed at GBX 0.06 ($0.00).
Nuformix Stock Up 7.1 %
The company has a quick ratio of 3.35, a current ratio of 1.12 and a debt-to-equity ratio of 1.17. The business has a 50-day simple moving average of GBX 0.13 and a 200-day simple moving average of GBX 0.17. The company has a market cap of £491,586.00, a PE ratio of -1.63 and a beta of 1.22.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Read More
- Five stocks we like better than Nuformix
- How to Effectively Use the MarketBeat Ratings Screener
- MercadoLibre Targets Double-Digit Upside with Argentina Boom
- Buy P&G Now, Before It Sets A New All-Time High
- Domino’s Pizza Stock Delivers: A Hot Buy for Growth Investors
- The Risks of Owning Bonds
- 3 Small-Cap Stocks Ready to Deliver Significant Growth
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
